POLYUNSATURATES AND KC1 TO CONTROL MILD HYPERTENSION

三项针对轻度高血压患者的随机安慰剂对照临床试验 建议用来评估膳食多不饱和脂肪酸的降压潜力 鱼油中的脂肪酸和膳食镁中的脂肪酸 补充钾。 1.鱼油中的n-3(omega-3)脂肪酸有利于平衡 在扩张和收缩血管的前列腺素和降压之间 在正常志愿者中也发现了鱼油的影响。因此，两个 高纯度和标准化的n-3脂肪酸制剂的剂量， 4g/d，8g/d，用于30例高血压患者，共3次 三个月，在交叉设计中，第三个三个月期间服用安慰剂。 2.镁主要是一种细胞内的阳离子，可以松弛光滑 动物模型中的肌肉，部分是通过减少细胞内 血管收缩药的浓度，钙。有提示性 有证据表明，在人类中，全身血压(BP)通过 补充镁。此外，由于饮食中的镁调节 细胞含钾量，这两种阳离子之间可能存在协同作用。 来降低血压。因此，120名未经治疗的轻度高血压患者将 随机分成四组，每组30人，每天接受6次治疗 月1)镁，375毫克，2)钾60毫克，3)镁和 钾，或匹配的安慰剂。目的：研究丹参降压作用机制。 镁，细胞内镁和游离钙的变化 在受试者的血液单个核细胞中确定，并与 英国石油公司的变化。 3.镁和钾的类似试验将在温和的情况下进行 利尿剂耗尽后正在接受利尿剂治疗的高血压患者 镁和钾，口服补充剂的降压作用可能会增强。 在整个研究过程中，将在多个场合测量血压 在诊所和受试者家中提供广泛的记录 治疗效果。每项研究都将有超过90%的能力来检测 4 mm收缩压治疗与安慰剂相比有显著的降压作用 舒张压3 mm。每一项遵守情况的生化验证 会得到治疗的。 一种治疗轻度高血压的有效膳食补充剂的发现 将具有极大的兴趣和实际意义。

Three randomized placebo-controlled clinical trials in mild hypertensives are proposed to assess the hypotensive potential of dietary polyunsaturated fatty acids in fish oil, and of dietary magnesium, alone and with supplemental potassium. 1. The n-3 (omega-3) fatty acids in fish oil favorably affect the balance between vasodilating and vasoconstricting prostanoids, and hypotensive effects of fish oils have been found in normal volunteers. Therefore, two doses of a highly purified and standardized preparation of n-3 fatty acids, 4g and 8g/d, will be administered to 30 hypertensive patients for three months, and placebo for a third three-month period in a crossover design. 2. Magnesium is primarily an intracellular cation that relaxes smooth muscle in animal models, in part by decreasing the intracellular concentration of the vasoconstrictor, calcium. There is suggestive evidence that, in humans, systemic blood pressure (BP) is lowered by supplemental magnesium. Moreover, since dietary magnesium regulates cellular potassium content, synergism may exist between these two cations for lowering BP. Therefore, 120 untreated mild hypertensives will be randomized into four groups of 30 subjects who will receive daily for six months either 1) magnesium, 375mg, 2) potassium 60mmoles, 3) magnesium and potassium, or 4) matching placebos. To study the hypotensive mechanism of magnesium, changes in intracellular magnesium and free calcium will be determined in the subjects' blood mononuclear cells and related to the changes in BP. 3. A similar trial of magnesium and potassium will be conducted in mild hypertensives who are being treated with diuretics since diuretics deplete Mg and K and the hypotensive effect of oral repletion may be potentiated. Blood pressure will be measured on multiple occasions throughout the study at the clinic and at the subjects' homes to provide an extensive record of treatment effects. Each study will have over 90% power to detect a significant hypotensive effect of treatment over placebo of 4mm systolic and 3mm diastolic BP. Biochemical validation of compliance with each treatment will be obtained. The discovery of an effective dietary supplement to treat mild hypertension would be of great interest and practical importance.